The present and future of neoadjuvant endocrine therapy for breast cancer treatment
Endocrine therapy (ET) has established itself as an efficacious treatment for estrogen receptor‐positive (ER+) breast cancers, with a reduction in recurrence rates and increased survival rates. The pre‐surgical approach with chemotherapy (NCT) has become a common form of management for large, locall...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universidad Autónoma de Madrid |
| Repositorio: | Biblos-e Archivo. Repositorio Institucional de la UAM |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.uam.es:10486/716779 |
| Acceso en línea: | http://hdl.handle.net/10486/716779 https://dx.doi.org/10.3390/cancers13112538 |
| Access Level: | acceso abierto |
| Palabra clave: | Breast cancer Endocrine therapy Neoadjuvant Resistance Medicina |
| Sumario: | Endocrine therapy (ET) has established itself as an efficacious treatment for estrogen receptor‐positive (ER+) breast cancers, with a reduction in recurrence rates and increased survival rates. The pre‐surgical approach with chemotherapy (NCT) has become a common form of management for large, locally advanced, or high‐risk tumors. However, a good response to NCT is not usually expected in ER+ tumors. Good results with primary ET, mainly in elderly women, have encouraged studies in other stages of life, and nowadays neoadjuvant endocrine treatment (NET) has become a useful approach to many ER+ breast cancers. The aim of this review is to provide an update on the current state of art regarding the present and the future role of NET |
|---|